Tesamorelin calculator
A GHRH analog approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy.
Also known as: Egrifta
FDA status FDA-approved as Egrifta for HIV-associated lipodystrophy. Use for any other purpose is off-label and requires a prescribing clinician's judgment.
This draw does not fit the selected syringe.200 units exceeds the 100-unit barrel. Choose a larger syringe, use less bacteriostatic water, or split the dose.
Schedule Tesamorelin → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Tesamorelin is
Tesamorelin is a stabilized GHRH analog approved as Egrifta specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. It is the only peptide in this class with a current FDA approval and a full trial dataset.
Research depth: 5/5 Full phase 3 human trial program supporting its FDA approval, with long-term safety follow-up. Human trials: Phase 3 trials. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Tesamorelin works
A trans-3-hexenoyl group added to the GHRH molecule protects it from rapid enzymatic breakdown, so it survives long enough to stimulate pituitary GHRH receptors effectively. The resulting rise in growth hormone and IGF-1 preferentially mobilizes visceral fat.
Tesamorelin side effects
Commonly reported
- Injection-site redness, itching, or pain
- Joint pain and muscle aches
- Swelling in the arms and legs from fluid retention
- Nausea
- Tingling or numbness in the extremities
Serious — seek medical care
- Increased blood glucose and new-onset or worsening diabetes
- Fluid retention severe enough to cause carpal tunnel syndrome
- Hypersensitivity reactions
- Contraindicated in active malignancy and in pregnancy
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 2 mg vial reconstituted with 2 mL of bacteriostatic water gives 1 mg/mL. A 2000 mcg dose is then 2 mL — about 200 units on a 100-unit insulin syringe, giving roughly 1 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Tesamorelin dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Tesamorelin run from 1000 mcg to 2000 mcg. The approved product carries its own labeled dose and reconstitution instructions — follow those, not a general calculator.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Tesamorelin at all are decisions for a licensed clinician who knows your history.
Common questions
How is tesamorelin reconstituted?
The approved product ships with specific instructions and its own diluent. Follow the package labeling. This calculator is here to check arithmetic, not to replace the label.
Is tesamorelin the same as other GHRH peptides?
It is in the same class as sermorelin and CJC-1295 but is a distinct molecule with its own approval, labeling, and safety data.